Earnings
Roivant CEO Resists Inventory Breakdown For $31 Million Launch As December Sales Face Drag
Pharmacies bought ahead of patient use in September, and management expects stocking to modestly depress December sales.
Roivant Sciences (ROIV) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Pharmacies bought ahead of patient use in September, and management expects stocking to modestly depress December sales.
SEC Filings
LISRAYA’s launch raised selling costs, while arthritis, eye-disease and lung-disease trials advanced.
SEC Filings
Median time to treatment failure topped 48 weeks on the pill versus about 12 weeks on placebo in each of two late-stage studies.